COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil*

Abstract

Objective: This cross-sectional study with dentists in Brazil assessed the COVID-19 incidence and severity, its vaccination status, and the level of confidence in vaccines in May 2021 (COVID-19 second wave). The medications used to prevent or treat COVID-19, including controversial substances (vitamin D, ivermectin, zinc, and chloroquine), were analyzed. Methodology: Dentists were recruited by email and responded to a pretested questionnaire until May 31, 2021. Bivariate and multivariate regression analyses were performed (α=0.05). Prevalence ratios were calculated for the association between professional characteristics and two outcomes: SARS-CoV-2 infection and use of controversial substances. Results: In total, 1,907 responses were received (return rate of 21.2%). One third of dentists reported intermediate levels of confidence in the safety and efficacy of COVID-19 vaccines, but 96% had received at least one vaccine dose, mainly CoronaVac. The effect of the pandemic on dental practice was classified as lower/much lower, in comparison with the first wave, by 46% of participants. Moreover, 27% of dentists had already tested positive for SARS-CoV-2 and about 50% had relatives or friends who had been hospitalized or died from COVID-19. At least one medication was used by 59% of participants and 43% used two or more substances. Vitamin D (41%), ivermectin (35%), and zinc (29%) were the most frequent substances. More experienced dentists (≥21 years of professional experience) were 42% more likely to use controversial substances than less experienced dentists. The prevalence of use of controversial substances was 30% higher among dentists with residency or advanced training, such as postgraduate degrees, in comparison with participants holding MSc or PhD degrees. Participants with low confidence in vaccines were 2.1 times more likely to use controversial substances than participants with a very high confidence. Conclusion: The results of this study show the high severity of the COVID-19 pandemic in Brazil and raised questions about the use of scientific evidence by dentists in their decision to use controversial substances.

Keywords: COVID-19 vaccines. Vitamin D. Zinc. Ivermectin. Chloroquine.
Introduction

The COVID-19 pandemic imposed significant challenges to dentistry worldwide.1–3 Dental practice during the pandemic was associated with negative feelings among dentists, who presented high anxiety levels and fear of exposure to SARS-CoV-2 and infection at work.3–5 A study during the first wave in Brazil showed that regional COVID-19 incidence and mortality rates were associated with fear of SARS-CoV-2 infection in dental offices.3 Since the beginning of the pandemic, the Brazilian government has been criticized for being hostile to scientific evidence and unable to stop the spread of SARS-CoV-2.6,7 Until June 2022, COVID-19 caused more than 666,000 deaths in Brazil, which is one of the highest global mortality rates (about 313 deaths per 100,000 inhabitants).8 Amid an epidemiological crisis, a topic that has received great attention worldwide is the use of ineffective or controversial substances to prevent or treat COVID-19.9–12 This issue was the subject of investigational hearings in the Brazilian Senate, including the off-label use of hydroxychloroquine and ivermectin, among others. A recent article showed that a small set of poorly designed studies on medications played a significant role in misinformation during the COVID-19 first wave in Brazil,13 when vaccines were still not available. In this turbulent scenario of uncertainty about the future of the pandemic combined with fear and high risk of exposure to SARS-CoV-2 in dental offices, dentists could be inclined to self-medicate or use substances without proven efficacy against COVID-19. At the same time, hesitation about accepting vaccination has been an issue worldwide14,15 and the level of confidence in COVID-19 vaccines could be associated with the use of unproved medications. A recent study performed in Italy showed that 18% of participating dentists were hesitant about COVID-19 vaccines16 whereas another study showed that the willingness to receive a COVID-19 vaccine was higher in South America than in the USA and Russia.15 This study aimed to assess the COVID-19 incidence and severity among dentists in Brazil, as well as the use of medications to prevent or treat COVID-19, information on vaccination status, and their level of confidence in vaccines. This study was carried out in May 2021, during the COVID-19 second wave, and about 7.9% of the Brazilian population had a confirmed COVID-19 diagnosis.8 The second wave was one of the most severe periods of the pandemic in Brazil, as more than 180,000 deaths from COVID-19 occurred from March to May 2021.8 The results of this study could help in understanding the severity of the pandemic among dentists, as well as help dental and other health professionals to better understand the effect of COVID-19 and strengthen preparedness for future infectious disease outbreaks.

Methodology

Study design and ethical aspects

This cross-sectional study was performed in Brazil in May 2021, one year after the performance of a similar study with dentists in Brazil during the COVID-19 first wave.3 The study protocol was approved by the institutional review board (Protocol No. 4.015.536) and all research methods were in accordance with the Declaration of Helsinki. This study mainly aimed to address the effect of COVID-19 on dental practice and its associated aspects, including COVID-19 incidence, severity, medication use, and vaccination among dentists. A questionnaire which was developed and pretested in previous studies was used.3,17 All participants had to agree to participate in the study to access the questionnaire. They were instructed to print or save the first page of the questionnaire to retain a copy of the informed consent form. In accordance with open science practices, the study project, the questionnaire (in its original language), and the database of responses are available in an open platform (https://osf.io/dnbg; DOI:10.17605/OSF.IO/DNBGS). An English translation of the questionnaire is available at https://dx.doi.org/10.17605/OSF.IO/DNBGS. The Consensus-Based Checklist for Reporting of Survey Studies (CROSS) was used.18

Questionnaire development, content, and pretesting

Details on the development and pretesting of the original questionnaire were previously published.3,17 A self-administered electronic questionnaire was used. It underwent minor revisions, including the exclusion of 11 and the addition of five questions most of them about COVID-19 severity, medication use, and vaccination which were not present in the previous versions of the questionnaire. The new questions were formulated based on the inputs of three researchers.
in three discrete rounds of revision.

The questionnaire was created on SurveyMonkey (Momentive Inc., San Mateo, CA, USA). Its first section presented the title and objective of the study and informed that the invitation was extended only to dentists. This section provided the informed consent form, which explained that the participation was voluntary and unpaid and showed the potential risks and benefits of the study. Moreover, it assured that all responses would be anonymous and confidential. Multiple participations from a same respondent were not allowed by the surveying system, which also protected the questionnaire from unauthorized access. Each question was presented to participants only after they responded to the previous question, showing that there were no discrete screens. The questionnaire had 25 mandatory items (one open- and 24 close-ended questions) about demographic and professional characteristics (n=6), professional practices and challenges during the pandemic (n=13), and COVID-19 vaccination, prevalence, severity, and medication (n=6). The items were not randomized and no adaptive questioning methods were used. All responses could be revised using back buttons at any time before submitting the completed form. In order to reduce bias related to response errors (units), the options “I'd rather not say,” “I don't know how to answer it,” and “Does not apply to me” were considered missing data. No strategies for weighting items, propensity scores, or sensitivity analysis were used. In analyses using data from the question on medication use, vitamin D, ivermectin, zinc, and chloroquine/hydroxychloroquine were considered controversial substances. Descriptive statistics were used to identify variable frequencies and distributions with respective 95% confidence intervals (CI). Bivariate and multivariate Poisson regression analyses were performed and prevalence ratios (PR) were estimate for the association between professional characteristics and two COVID-19-related outcomes: SARS-CoV-2 infection and use of controversial substances by dentists. Variable selection in the multivariate models was performed using the backward stepwise method. Variables from the bivariate analysis were considered only if p<0.25. All analyses were performed in Stata 14.2 (StataCorp, College Station, TX), considering α=0.05.

Results

Of the 24,392 emails sent to dentists, 1,347 bounced (loss of 5.5%) and 9,010 were opened (unique visitors), as registered by the surveying system (view proportion=36.9%). A return rate of 21.2% was calculated from the opened emails and 1,907 valid responses were received from all 26 Brazilian states and the Federal District.

Sample characteristics

The length of work experience and levels of postgraduate education varied among participants (Table 1). There was a predominance of responses
Table 1- Characteristics of the sample of Brazilian dentists, 2021 (n=1,907)

| Variable/category                                      | n*  | %     | 95% CI          |
|--------------------------------------------------------|-----|-------|-----------------|
| **Sex**                                                |     |       |                 |
| Women                                                  | 1,414 | 74.1 | 72.1; 76.1      |
| Men                                                    | 493  | 25.9 | 23.9; 27.9      |
| **Years of professional experience**                   |     |       |                 |
| ≤5                                                     | 451  | 23.7 | 21.8; 25.6      |
| 6–10                                                   | 474  | 24.9 | 23.0; 26.9      |
| 11–20                                                  | 534  | 28.0 | 26.1; 30.1      |
| >20                                                    | 446  | 23.4 | 21.6; 25.4      |
| **Postgraduate education (complete)**                  |     |       |                 |
| None                                                   | 505  | 26.6 | 24.7; 28.7      |
| Residency or advanced special training                 | 997  | 52.5 | 50.2; 54.7      |
| MSc or PhD                                             | 397  | 20.9 | 19.1; 22.8      |
| **Main work sector**                                   |     |       |                 |
| Public                                                 | 1,106 | 58.5 | 56.1; 60.6      |
| Private                                                | 613  | 32.4 | 30.3; 34.5      |
| Other                                                  | 173  | 9.1  | 8.0; 10.7       |
| **Region of Brazil**                                   |     |       |                 |
| South                                                  | 586  | 30.7 | 28.7; 32.9      |
| Southeast                                              | 552  | 29.0 | 26.8; 30.9      |
| Northeast                                              | 552  | 29.0 | 27.1; 31.2      |
| Central West                                           | 139  | 4.0  | 3.2; 5.0        |
| North                                                  | 77   | 7.3  | 6.2; 8.6        |
| **COVID-19 vaccination status**                        |     |       |                 |
| Not vaccinated                                         | 76   | 4.0  | 3.2; 5.0        |
| Partially vaccinated                                   | 188  | 9.9  | 8.5; 11.2       |
| Fully vaccinated                                       | 1,13  | 61  | 64.6; 67.7      |
| **Vaccines received**                                  |     |       |                 |
| CoronaVac (Sinovac/Butantan)                           | 1,17  | 64.9 | 62.7; 67.1      |
| Oxford (AstraZeneca/Fiocruz)                           | 622  | 34.2 | 32.0; 36.4      |
| Pfizer (BioNTech)                                      | 17   | 0.9  | 0.5; 1.4        |
| **Level of confidence in the safety and efficacy of COVID-19 vaccines** | 1,856 |       |                 |
| Very low                                               | 59   | 3.2  | 2.3; 4.0        |
| Low                                                    | 104  | 5.6  | 4.1; 6.3        |
| Intermediate                                           | 611  | 32.9 | 30.5; 35.2      |
| High                                                   | 712  | 38.4 | 36.3; 41.1      |
| Very high                                              | 370  | 19.9 | 18.4; 22.4      |
| **Effect of the COVID-19 pandemic on dental practice in comparison with one year before (May 2020, first wave in Brazil)** | 1,749 |       |                 |
| Much lower                                             | 154  | 8.8  | 7.5; 10.4       |
| Lower                                                  | 648  | 37.1 | 36.0; 40.8      |
| Similar                                                | 528  | 30.2 | 28.5; 31.9      |
| Higher                                                 | 240  | 13.7 | 12.5; 15.9      |
| Much higher                                            | 179  | 10.2 | 8.6; 11.6       |
| **How prepared do you feel to treat patients with COVID-19?** | 1,743 |       |                 |
| Not at all prepared                                    | 412  | 23.6 | 21.7; 25.9      |
| Poorly prepared                                        | 268  | 15.4 | 14.1; 17.7      |
| Moderately prepared                                    | 486  | 27.9 | 25.5; 30.9      |
| Well prepared                                          | 434  | 24.9 | 22.6; 26.9      |
| Very well prepared                                     | 143  | 8.2  | 6.9; 9.7        |
| **Fear of being infected at work**                     | 1,766 |       |                 |
| None                                                   | 354  | 20.0 | 18.0; 22.0      |
| Little                                                 | 553  | 31.3 | 29.5; 34.2      |
| Moderate                                               | 450  | 25.5 | 23.6; 28.0      |
| High                                                   | 409  | 23.2 | 20.5; 24.7      |
| **Frequency of use of N95 masks in dental appointments** | 1,71  |       |                 |
| Never                                                  | 100  | 5.9  | 4.8; 7.1        |
| Perceived higher risk of COVID-19                      | 64   | 3.7  | 2.9; 4.8        |
| Aerosol-generating procedures                          | 127  | 7.4  | 6.3; 9.0        |
| Wherever it is available                               | 237  | 13.9 | 11.7; 15.1      |
| Always                                                 | 1,182 | 69.1 | 67.2; 71.8      |
| **Frequency of use of face shields in dental appointments** | 1,699 |       |                 |
| Never                                                  | 159  | 9.4  | 7.6; 10.5       |
| Perceived higher risk of COVID-19                      | 90   | 5.3  | 4.5; 6.8        |

Continued on the next page
from women and dentists in the public sector. In total, 88.7% of participants worked in Southern, Southeastern, and Northeastern Brazil. By May 2021, 96% of dentists had received at least one dose of the COVID-19 vaccine and the most common vaccine was CoronaVac (65%). There was a predominance of high and very high levels of confidence in COVID-19 vaccines (58%), but one third of the sample reported intermediate levels of confidence in the safety and efficacy of the vaccines.

Current effect of COVID-19 on dental practice
The effect of the pandemic on dental practice during the second wave was classified as lower/much lower, in comparison with the first wave, by 46% of participants. However, 39% felt poorly or not prepared to treat patients with COVID-19 and 49% reported moderate or high fear of being infected with the SARS-CoV-2 during work. N95 masks and face shields were always used in dental appointments by at least 60% of dentists and 27% treated patients with confirmed COVID-19.

COVID-19 incidence, severity, and medication use
In total, 27% of dentists had already tested positive for SARS-CoV-2 by May 2021 and most of them were asymptomatic or had mild symptoms (88%). Moreover, 49.8% had relatives or friends who had been hospitalized or died from COVID-19. Regarding medication use, 58.9% of participants used at least one of the seven controversial substances listed in Table 1 to prevent or treat COVID-19. Vitamin D was the most common (41%), followed by ivermectin (35%), zinc (29%), and azithromycin (27%). The use of chloroquine or hydroxychloroquine was not prevalent (4%). A total of 74.7% of participants who tested positive for SARS-CoV-2 used at least one of

| Substance used to prevent or treat COVID-19** | 1 | 2 | 3 | 4 or more |
|---------------------------------------------|---|---|---|-----------|
| Vitamin D + zinc + ivermectin               | 106| 6.8| 5.6| 8.2       |
| Vitamin D + zinc                            | 101| 6.5| 5.3| 7.8       |
| Chloroquine/hydroxychloroquine + ivermectin + zinc + vitamin D | 61| 3.9| 3.0| 5.0 |
| Ivermectin + zinc                          | 53| 3.4| 2.6| 4.4       |
| Vitamin D                                  | 251| 16.2| 14.4| 18.1     |
| Chloroquine/hydroxychloroquine             | 252| 16.2| 14.4| 18.1     |
| Ivermectin                                 | 217| 14.0| 12.3| 15.9     |
| Chloroquine/hydroxychloroquine             | 195| 12.5| 10.9| 14.2     |
these substances whereas the frequency of this use among dentists who tested negative was 52.4%. In total, 42.7% of dentists used two or more substances. The most frequent combination was vitamin D and zinc combined or not with ivermectin.

Table 2 presents the prevalence ratios for the association between professional characteristics and SARS-CoV-2 infection. Sex, work sector, and years of professional experience were not associated with the prevalence of infection. Dentists working in Northern Brazil were 58% more likely to be infected than those working in Southern Brazil. Dentists with residency or advanced training, such as postgraduate education, were 26% more likely to be infected than professionals with MSc or PhD degrees. The level of confidence in COVID-19 vaccines was not associated with a history of infection. Participants who reported no fear of being infected at work were 48% more likely to be infected with COVID-19 than those who reported high fear.

Table 3 presents the prevalence ratios for the association between professional characteristics and the use of controversial substances in the multivariate analysis. Sex and work sector were not associated with the use of controversial substances. However, more experienced dentists (>21 years of professional experience) were 42% more likely to use controversial substances than less experienced dentists. Participants from the Central Western, Northern, and Northeastern Brazil were from 29% to 37% more likely to use controversial substances than participants from Southern Brazil. The prevalence of use of controversial substances was 30% higher among dentists with residency or advanced training, such as postgraduate education, in comparison with participants holding MSc or PhD degrees. The level of confidence in COVID-19 vaccines also influenced medication use. The increased prevalence of controversial medication use was associated with decreased levels of confidence in vaccines. Participants with low confidence in COVID-19 vaccines, for instance, were 2.1 times more likely to

| Variable                      | PR² | 95% CI     | PRᵃ | 95% CI     |
|-------------------------------|-----|------------|-----|------------|
| Sex                           |     |            |     |            |
| Men                           | 1   | *          | *   |            |
| Women                         | 0.97| 0.81; 1.15 |     |            |
| Main work sector              |     |            |     |            |
| Public                        | 1   | *          | *   |            |
| Private                       | 0.87| 0.73; 1.74 |     |            |
| Others                        | 0.84| 0.62; 1.13 |     |            |
| Years of professional experience |    |            |     |            |
| ≤10                           | 1   | *          | *   |            |
| 11–20                         | 1.29| 1.05; 1.59 |     |            |
| ≥21                           | 1.17| 0.93; 1.48 |     |            |
| Region of Brazil              |     |            |     |            |
| South                         | 1   | 1          |     |            |
| Southeast                     | 0.77| 0.62; 0.95 | 0.78| 0.63; 0.98 |
| Northeast                     | 1.12| 0.92; 1.35 | 1.16| 0.95; 1.41 |
| North                         | 1.52| 1.10; 2.11 | 1.58| 1.14; 2.20 |
| Central West                  | 0.94| 0.68; 1.31 | 0.94| 0.67; 1.32 |
| Postgraduate education        |     |            |     |            |
| MSc or PhD                    | 1   | 1          |     |            |
| Residency or advanced training | 1.27| 1.03; 1.57 | 1.26| 1.02; 1.57 |
| None                          | 1.13| 0.88; 1.44 | 1.13| 0.88; 1.45 |
| Confidence in COVID-19 vaccines |     |            |     |            |
| Very high                     |     |            |     |            |
| High                          | 1.18| 0.94; 1.49 |     |            |
| Moderate                      | 1.24| 0.98; 1.57 |     |            |
| Low                           | 1.33| 0.92; 1.93 |     |            |
| Very low                      | 1.60| 1.07; 2.38 |     |            |
| Fear of being infected at work |     |            |     |            |
| High                          | 1   | 1          |     |            |
| Moderate                      | 1.03| 0.81; 1.31 | 1.04| 0.82; 1.32 |
| Little                        | 0.97| 0.77; 1.22 | 0.99| 0.79; 1.25 |
| None                          | 1.43| 1.14; 1.80 | 1.48| 1.18; 1.85 |

CI: Confidence Interval. *Not included in the multivariate analysis.
use controversial substances than participants with a very high confidence in vaccines.

Discussion

This study showed a high prevalence of COVID-19 among Brazilian dental professionals (27%) and a frequent occurrence of hospitalization and death from this disease among their relatives or friends during the second wave. Moreover, 59% of participants used one or more substances to prevent or treat COVID-19, including vitamin D, zinc, and ivermectin, which have limited evidence to support their clinical use against COVID-19.

Studies conducted in several countries showed varying prevalence of COVID-19 among dentists: 1.1% in Brazil (May 2020), 9.1% in Belgium (July–Sept. 2020), 2.6% in the USA (June–Nov. 2020), 4.9% in Latin America (Sep.–Dec. 2020), 10.9% in Italy (Dec. 2020–Jan. 2021), and 1.1% in Canada (July 2020–Feb. 2021). In a multi-country study performed in 2020, about 15% of dentists reported COVID-19 symptoms and a prevalence rate of 25% was observed in Czech Republic (June 2021). The differences in contraction rates could be partially explained by distinct public health measures in response to the pandemic and different COVID-19 spreading rates in the countries. In this study, for example, the prevalence of COVID-19 was higher in Northern than in Southern Brazil, which could be related to the abrupt increase in the number of cases in Manaus, Northern Brazil, during the first months of 2021. The high prevalence of dentists who tested positive for COVID-19 could also be associated with the long-lasting trend of new daily cases of this disease in Brazil, which continued to have high rates of virus transmission during 2020 (first wave) and had an increase in number of cases in the first half of 2021 (second wave).

About 50% of participants had relatives or friends who had been hospitalized or died from COVID-19. This result is worrying and highlights the severity of the pandemic in Brazil, as COVID-19 was the leading cause of deaths in the public health system during 2020 and 2021. Although the effect on dental practice in May 2021 seemed to be lower when compared with May

| Variable                  | PR 95% CI | PR 95% CI |
|---------------------------|-----------|-----------|
| Sex                       |           |           |
| Men                       | 1         | 1         |
| Women                     | 1.11 (0.98; 1.25) | 1.09 (0.97; 1.23) |
| Main work sector          |           |           |
| Public                    | 1         | 1         |
| Private                   | 1.09 (0.99; 1.22) | 1.10 (0.99; 1.23) |
| Other                     | 0.56 (0.43; 0.74) | 0.76 (0.58; 1.00) |
| Years in practice         |           |           |
| ≤10                       | 1         | 1         |
| 11–20                     | 1.17 (1.04; 1.33) | 1.18 (1.03; 1.35) |
| ≥21                       | 1.38 (1.22; 1.55) | 1.42 (1.26; 1.61) |
| Region of Brazil          |           |           |
| South                     | 1         | 1         |
| Southeast                 | 0.99 (0.86; 1.15) | 0.98 (0.85; 1.13) |
| Northeast                 | 1.29 (1.14; 1.48) | 1.37 (1.20; 1.57) |
| North                     | 1.37 (1.08; 1.73) | 1.37 (1.07; 1.76) |
| Central West              | 1.29 (1.07; 1.57) | 1.29 (1.07; 1.57) |
| Postgraduate education    |           |           |
| MSc or PhD                | 1         | 1         |
| Residency or advanced special training | 1.52 (1.30; 1.77) | 1.30 (1.11; 1.53) |
| None                      | 1.31 (1.10; 1.57) | 1.19 (0.98; 1.43) |
| Confidence in COVID-19 vaccines |     |           |
| Very high                 | 1         | 1         |
| High                      | 1.38 (1.14; 1.66) | 1.31 (1.09; 1.58) |
| Moderate                  | 1.90 (1.59; 2.27) | 1.65 (1.37; 1.99) |
| Low                       | 2.21 (1.77; 2.76) | 1.94 (1.55; 2.42) |
| Very Low                  | 2.50 (1.97; 3.16) | 2.14 (1.67; 2.75) |

CI: Confidence Interval.
participants still frequently felt poorly prepared to treat patients with COVID-19 and had moderate to high fear of being infected by this disease at work. Dentists who reported no fear of being infected by the disease were more likely to be infected by COVID-19, which raises questions about the influence of the more or less strict preventive measures adopted by them. Moreover, the high risk of SARS-CoV-2 infection in dental offices, along with the frequent occurrence of COVID-19 among dentists’ relatives and friends, could be associated with high levels of psychosis and anxiety, which may help to explain the high prevalence of use of off-label medication for COVID-19.

Misinformation has been a major problem in the pandemic and a potential source of public confusion and controversy. A study in Vietnam showed that more than 91% of health professionals learned about COVID-19 via social media, which are digital places where the content of information is not policed. Health professionals are expected to keep themselves up to date with reliable information to educate and treat their patients. However, they have been reported as the major practitioners of self-medication. Scientific literature plays an important role in this context of professional practices. This is highlighted by the observation that dentists holding MSc or PhD degrees were less likely to use controversial substances. This finding could be related to the type of education and the generally longer duration of MSc and PhD courses when compared with specialized clinical training courses. We also found that more experienced dentists were more likely to use controversial substances than less experienced dentists, which could be associated with the higher risk of older adults of having severe cases of COVID-19. Participants with low confidence in COVID-19 vaccines were 2.1 times more likely to use controversial substances than participants with a high confidence in these vaccines. To the best of our knowledge, this is the first study to show this association.

Among many factors that may negatively interfere with evidence-based health practice in the pandemic context, there is the large number of low-quality studies reporting conflicting results for the treatment of COVID-19. This is associated with difficulties of implementing the best available evidence due to lack of time, knowledge, or skills to critically evaluate the literature. This means that controversial substances could be considered either effective or ineffective depending on the article selected and how it was interpreted. Regarding vitamin D, for instance, a systematic review suggested that its supplementation was associated with reduced intensive care unit (ICU) admission, the need for mechanical ventilation, and mortality. Another systematic review showed that vitamin D did not reduce the risk of these clinical outcomes. A meta-analysis showed that zinc reduced COVID-19 death rates whereas a different meta-analysis showed that there is no evidence to support zinc supplementation in patients with COVID-19. Karale et al. (2021) stated that the treatment of COVID-19 with ivermectin may reduce the need for hospitalization, but a living network meta-analysis showed that it was highly uncertain whether ivermectin used as a preventive measure would reduce the risk of SARS-CoV-2 infection. Another frequent problem is the presence of methodological issues across the primary studies. In all aforementioned systematic reviews, the authors highlighted that more randomized controlled trials with larger sample sizes and less risk of bias, imprecision, and/or heterogeneity were necessary. It seems that the topic of controversial substances to prevent or treat COVID-19 will still attract attention in the following years, as definitive conclusions will hardly be accepted universally. In the meantime, dentists are encouraged to rely on evidence with low risk of bias and good methodological quality or evidence-based guidelines, when available.

A positive finding of this study was the high rate of COVID-19 vaccination. In Brazil, health professionals were priorities for vaccination, followed by older adults, thus, dentists were vaccinated in the first stages of the immunization program with the first vaccines available in Brazil. This explains the high frequency of dentists who received CoronaVac, which was the first vaccine authorized for emergency use by the Brazilian Health Regulatory Agency in January 2021. This vaccine was developed by the Instituto Butantan in association with the Chinese laboratory Sinovac. A study showed that the rapid increase in vaccination of Brazilian older adults with CoronaVac was associated with a significant decline in mortality. This vaccine was criticized by President Bolsonaro and his allies during its testing phases in 2020. In that period, a study showed that Brazilians were less likely to accept vaccination when the country of origin of the vaccine was mentioned. Since January 2022, four vaccines
have been available for use in Brazil and dentists throughout the country are eligible to take booster shots. Further studies could evaluate the acceptance of dental professionals to the new phases of COVID-19 vaccination and the maintenance of other preventive measures to address whether the so-called "pandemic fatigue" may decrease their adherence to individual and collective risk reduction strategies.40

This study had limitations and care should be taken when extrapolating its results. Participants were free either to accept or not the invitation to participate in the study, which may have led to self-selection bias, increasing the chances of dentists who were more concerned about the pandemic and perhaps more willing to use medications to participate. Moreover, we did not collect data on doses or frequency of use of substances, which may have varied greatly among participants. Self-reported SARS-CoV-2 infection was another limitation, as the diagnosis could be influenced by variations in quality and accuracy across molecular and serologic tests. Moreover, self-reported medication use may have been influenced by social-desirability bias, but the questionnaire was anonymous and thus this influence could be low. A strength of this study was that a large sample of dentists was recruited in a period when Brazil was struggling to deal with the pandemic. Further studies could address the use of controversial substances and the socioeconomical aspects involved.

Conclusion

This study with dentists during the COVID-19 second wave in Brazil showed a high incidence of this disease among dentists, a frequent occurrence of hospitalization and death from COVID-19 among their relatives or friends, and a very frequent use of controversial substances to prevent or treat COVID-19. The COVID-19 vaccination status was high among the studied dentists. The overall findings highlighted the high severity of the pandemic in Brazil and raised questions about the use of scientific evidence by dentists in their decision to use controversial substances, such as vitamin D, zinc, and ivermectin.

Acknowledgments

This study was funded by the Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Brazil (PRONEX 16/2551-0000471-4; grant recipient FFD), and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil (Finance Code 001; institutional grant). The funders did not contribute to the study design, data collection, analysis, or interpretation, article writing, or approval for publication.

Conflict of interest

The authors declare no conflict of interest.

Data availability statement

The data generated during this study are available in the OSF repository [DOI: 10.17605/OSF.IO/DNBGS].

Authors’ contributions

Moraes, Rafael R.: Conceptualization (Lead); Data curation (Lead); Formal analysis (Supporting); Investigation (Lead); Methodology (Lead); Project administration (Lead); Resources (Lead); Supervision (Lead); Validation (Lead); Visualization (Lead); Writing – original draft (Lead). Correa, Marcos Britto: Conceptualization (Equal); Data curation (Supporting); Formal analysis (Lead); Investigation (Supporting); Validation (Supporting); Visualization (Supporting); Writing – review & editing (Supporting). Martins-Filho, Paulo R.: Data curation (Supporting); Visualization (Supporting); Writing – original draft (Supporting); Writing – review & editing (Supporting). Lima, Giana da Silveira: Conceptualization (Supporting); Writing – review & editing (Supporting). Demarco, Flavio Fernando: Conceptualization (Supporting); Funding acquisition (Lead); Resources (Lead); Writing – review & editing (Supporting).

References

1- Novaes TF, Jordão MC, Bonacina CF, Veronezi AO, Araujo CA, Olegário IC, et al. COVID-19 pandemic impact on dentists in Latin America’s epicenter: São-Paulo, Brazil. PLoS One. 2021;16(8):e0256092. doi: 10.1371/journal.pone.0256092
2- Mekhemar M, Attia S, Dörfer C, Conrad J. The psychological impact of the COVID-19 pandemic on dentists in Germany. J Clin Med. 2021;10(5):1008. doi: 10.3390/jcm10051008
3- Moraes RR, Correa MB, Queiroz AB, Daneris A, Lopes JP, Pereira-Cenci T, et al. COVID-19 challenges to dentistry in the new pandemic epicenter: Brazil. PLoS One. 2020;15(11):e0242251. doi: 10.1371/journal.pone.0242251
4- Sharma A, Chhabra KG, Bhardani SS, Poddar G, Dany SS, Chhabra C, et al. Emotional well-being of dentists and the effect of lockdown during the COVID-19 pandemic: a nationwide study. J Educ Health Promot. 2021;10:344. doi: 10.4103/jehp.jehp_1337_20

5- Chen Y, Li W. Influencing factors associated with mental health outcomes among dental medical staff in emergency exposed to Coronavirus Disease 2019: a multicenter cross-sectional study in China. Front Psychiatry. 2021;12:736172. doi: 10.3389/fpsyt.2021.736172

6- Ortega F, Orsini M. Governing COVID-19 without government in Brazil: ignorance, neoliberal authoritarianism, and the collapse of public health leadership. Glob Public Health. 2020;15(9):1257-77. doi: 10.1080/17441692.2020.1795223

7- Boschiero MN, Palamim CV, Ortega MM, Mauch RM, Marson FA. One year of Coronavirus Disease 2019 (COVID-19) in Brazil: a political and social overview. Ann Glob Health. 2021;87(1):44. doi: 10.5334/aogh.3182

8- World Health Organization. WHO Coronavirus (COVID-19) dashboard [Internet]. Geneva: WHO; c2022 [cited 2022 Aug 29]. Available from: https://covid19.who.int/

9- Lasgo G, Yu VG. Pharmaceutical messianism and the COVID-19 pandemic. Soc Sci Med. 2021;114567. doi: 10.1016/j.socscimed.2021.114567

10- Arshad AR, Tiaz F, Siddiqui MS, Khalid S, Fatima A, Ahtab RK. COVID-19 pandemic and antimicrobial resistance in developing countries. Discoveries (Craiova). 2021;9(2):e127. doi: 10.15190/d.2021.6

11- Duncan EM, Goulao B, Clarkson J, Young L, Ramsay CR. “You had to do something”: prescribing antibiotics in Scotland during the COVID-19 pandemic restrictions and remobilisation. Br Dent J. 2021;1:6. doi: 10.1038/s41415-021-3621-8

12- Martins-Filho PR, Ferreira LC, Heimfarth L, Araújo AA, Quintans-Júnior LJ. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. Lancet Reg Health Am. 2021;2:100062. doi: 10.1016/j.lana.2021.100062

13- Alves CP, Barreto Segundo JD, Costa GG, Pereira-Cenci T, Lima KC, Demarco FF, et al. How a few poorly designed COVID-19 studies may shape evidence-based communication of science. BMJ Open Sci. 2021;5(1):e100202. doi: 10.1136/bmjhos-2021-100202

14- Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron N. COVID-19 Prevalence among Czech Dentists. Int J Environ Res Public Health. 2021;18(16):8381. doi: 10.3390/ijerph18168381

20- Araujo MW, Estrich CG, Mikkelson M, Morrissey R, Harrison B, Geisinger ML, et al. COVID-19 among dentists in the United States: a 6-month longitudinal report of cumulative prevalence and incidence. J Am Dent Assoc. 2021;152(6):425-33. doi: 10.1016/j.adaj.2021.03.021

21- Moraes R, Cuevas-Suárez C, Escalante-Otárola W, Fernández M, Dávila-Sánchez A, Grau-Grullon P, et al. A multi-country survey on the impact of COVID-19 on dentists in Latin America. Res Square [Preprint], 2021. Available from: http://dx.doi.org/10.21203/rs.3.rs-764333/v1

22- Madathil S, Siqueira WL, Marin LM, Sanaula FB, Faraj N, Quiñones CR, et al. The incidence of COVID-19 among dentists practicing in the community in Canada: a prospective cohort study over a six-month period. J Am Dent Assoc. 2022;153(5):450-9.e1 doi: 10.1016/j.adaj.2021.10.006

23- COVID-19 Collaboration Group. The COVID-19 pandemic and its global effects on dental practice. An International survey. J Dent. 2021;14:103749. doi: 10.1016/j.jdent.2021.103749.

24- Schmidt J, Perina V, Treglerova J, Pilaurovova N, Suchanej J, Smucker R. COVID-19 Prevalence among Czech Dentists. Int J Environ Res Public Health. 2021;18(23):12488. doi: 10.3390/ijerph182312488

25- Ferrante L, Steinmetz WA, Almeida ACL, Leão J, Vassão RC, Tupinanambá U, et al. Brazil’s policies condemn Amazonia to a second wave of COVID-19. Nat Med. 2020;26(9):1315. doi: 10.1038/s41591-020-1026-x

26- Sabino EC, Buss LF, Carvalho MP, Prete CA Jr, Crispim MA, Fraigy NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet. 2021;397(10273):452-5. doi: 10.1016/S0140-6736(21)01883-5

27- Castro MC, Guzenda S, Turra CM, Kim S, Andrasfay T, Goldman N. Reduction in life expectancy in Brazil after COVID-19. Nat Med. 2021;27(9):1629-35. doi: 10.1038/s41591-021-01437-z

28- Huynh N, Nguyen TH, Tran V, Vo K, Vo V, Pham L. Knowledge and attitude toward COVID-19 among healthcare workers at District 2 Hospital, Ho Chi Minh City. Asian Pac J Trop Med. 2020;13(6):260-5. doi: 10.4103/1995-7645.280396

29- Apuke OD, Omar B. Fake news and COVID-19: modelling the predictors of fake news sharing among social media users. Telemat Inform. 2021;56:101475. doi: 10.1016/j.tele.2020.101475

30- Sisay M, Mengistu G, Edessa D. Epidemiology of self-medication in Ethiopia: a systematic review and meta-analysis of observational studies. BMC Pharmacol Toxicol. 2018;19(1):56. doi: 10.1186/s40360-018-0248-8

31- Sadio AJ, Kone KT, Konou Y, Bakoubayi AW, Chankoni NT, Tupinambás U, et al. Assessment of self-medication practices among health workers in the context of the COVID-19 outbreak in Togo. BMC Public Health. 2021;21(1):58. doi: 10.1186/s12889-020-10145-1

32- Hariyanto TI, Intan D, Harapan H, Kurniawan A. Vitamin D supplementation and Covid-19 outcomes: a systematic review, meta-analysis and meta-regression. Rev Med Virol. 2022;32(2):e2269. doi: 10.1002/rmv.2269

33- Szarpak L, Pruc M, Gasecka A, Jaguszewski MJ, Michalski T, Peacock MK, Bitty-Anderson AM, et al. Effect of micronutrient supplements on COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2022;32:e2022001610/11
37- Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis against COVID-19: living systematic review and network meta-analysis. BMJ. 2021;373:n949. doi: 10.1136/bmj.n949
38- Victora CG, Castro MC, Gurzenda S, Medeiros AC, França GV, Barros AJ. Estimating the early impact of vaccination against COVID-19 on deaths among elderly people in Brazil: analyses of routinely-collected data on vaccine coverage and mortality. EClinicalMedicine. 2021;38:101036. doi: 10.1016/j.eclinm.2021.101036
39- Gramacho WG, Turgeon M. When politics collides with public health: COVID-19 vaccine country of origin and vaccination acceptance in Brazil. Vaccine. 2021;39(19):2608-12. doi: 10.1016/j.vaccine.2021.03.080
40- Trogen B, Caplan A. Risk compensation and COVID-19 vaccines. Ann Intern Med. 2021;174(6):858-9. doi: 10.7326/M20-8251